8-K: CONMED Reports Mixed Q2 2025 Results, Raises Full-Year Adjusted EPS Guidance

CONMED Corporation announced second quarter 2025 financial results, reporting increased sales and adjusted diluted net earnings per share, alongside a decline in GAAP net earnings per share, and raised its full-year adjusted EPS guidance despite tariff impacts.

Summary

• Sales for the second quarter ended June 30, 2025, reached $342.3 million, marking a 3.1% increase year-over-year as reported and 2.9% in constant currency.
• Domestic revenue grew by 2.8% year-over-year, while international revenue increased 3.4% as reported and 2.9% in constant currency.
• Diluted net earnings per share (GAAP) were $0.69, a decrease from $0.96 in the second quarter of 2024.
• Adjusted diluted net earnings per share increased to $1.15, up from $0.98 in the second quarter of 2024.
• Gross profit was $188.320 million (55.0% of sales) in Q2 2025, compared to $183.729 million (55.3% of sales) in Q2 2024.
• Income from operations decreased to $38.161 million (11.1% of sales) in Q2 2025, from $47.107 million (14.2% of sales) in Q2 2024.
• Adjusted EBITDA for Q2 2025 was $68.601 million, with an adjusted EBITDA margin of 20.0%, compared to $64.590 million and 19.4% in Q2 2024.
• Full-year 2025 reported revenue guidance was updated to a range of $1.356 billion to $1.378 billion, a slight increase from the prior range of $1.350 billion to $1.378 billion.
• Full-year 2025 adjusted diluted net earnings per share guidance was raised to a range of $4.40 to $4.55, up from the prior range of $4.31 to $4.46.
• The updated guidance includes an estimated negative impact of approximately $0.09 to EPS in the second half of 2025 due to recent tariff announcements.

Sentiment

Score: 7

Explanation: While GAAP net earnings per share and operating income declined, the company demonstrated solid sales growth and a significant increase in adjusted diluted net earnings per share and adjusted EBITDA. The raised full-year guidance for adjusted EPS and the positive revision on currency headwinds indicate management's confidence and improved operational outlook, despite the negative impact of tariffs and a notable decline in capital product sales.

Positives

• Overall sales increased by 3.1% year-over-year, demonstrating continued revenue growth.
• Adjusted diluted net earnings per share grew significantly to $1.15 from $0.98, indicating improved underlying operational profitability.
• Adjusted EBITDA increased to $68.601 million with an improved margin of 20.0%, reflecting better operational efficiency.
• Full-year adjusted diluted net earnings per share guidance was raised, signaling management's increased confidence in future performance.
• The company now expects foreign currency exchange rate headwinds to be immaterial for full-year revenue, a positive revision from previous estimates of 50 to 70 basis points of headwind.
• Single-use products showed strong growth, with sales increasing 6.6% as reported and 6.4% in constant currency.

Negatives

• Diluted net earnings per share (GAAP) decreased to $0.69 from $0.96 in the prior year, indicating a decline in reported profitability.
• Net income decreased to $21.421 million from $29.976 million year-over-year.
• Income from operations declined to $38.161 million from $47.107 million, and its percentage of sales decreased from 14.2% to 11.1%.
• Gross profit percentage slightly decreased from 55.3% to 55.0%.
• Sales of Capital Products experienced a significant decline of 15.5% as reported and 15.6% in constant currency, potentially indicating reduced capital expenditure by healthcare providers.

Risks

• Recent tariff announcements are expected to result in a negative impact of approximately $0.09 to EPS in the second half of 2025.
• General industry and economic conditions could cause actual results, performance, or trends to differ materially from forward-looking statements.
• Risks and uncertainties detailed in the company's Annual Report on Form 10-K for the full year ended December 31, 2024, and most recently filed Form 10-Q.
• Ongoing costs for third-party services pertaining to potential issues with certain royalty payments to surgeons involved in design teams.

Future Outlook

The company updated its 2025 outlook, now expecting full-year reported revenue between $1.356 billion and $1.378 billion, a slight increase at the lower end of the previous guidance. Full-year adjusted diluted net earnings per share are now projected in the range of $4.40 to $4.55, an increase from the prior guidance. Foreign currency headwinds are anticipated to be immaterial for revenue and approximately 10 cents for EPS. This updated guidance incorporates an estimated negative impact of $0.09 to EPS in the second half of 2025 due to recent tariff announcements.

Management Comments

• "We are encouraged by our second quarter performance as we focused on building a stronger operational foundation."
• "We continue to strengthen our supply chain operations with a focus on turning this into an area of strength within CONMED."
• "We remain very confident in the long-term potential of our four key growth drivers and the solid foundation for sustained revenue and earnings growth that they provide."

Industry Context

Operating within the medical technology sector, CONMED's focus on strengthening its operational foundation and supply chain reflects broader industry trends towards resilience and efficiency in global supply chains, particularly post-pandemic. The strong performance in single-use products suggests robust demand for ongoing surgical procedures, while the decline in capital products might indicate a more cautious approach by healthcare providers towards large equipment investments, possibly due to economic pressures or shifting priorities. The company's emphasis on 'four key growth drivers' suggests a strategic focus on specific high-potential areas within the competitive MedTech landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global industry benchmarks.

Legal Proceedings

• The company incurred costs for third-party services pertaining to potential issues with certain royalty payments to surgeons involved in design teams in both 2025 and 2024.

Stakeholder Impact

• Shareholders: Mixed Q2 results with GAAP decline but strong adjusted performance and raised full-year guidance, potentially leading to positive sentiment for long-term investors.
• Employees: Operational optimization initiatives and executive transition costs indicate ongoing internal restructuring and strategic adjustments.
• Customers: Continued focus on strengthening supply chain operations aims to improve product availability and service.
• Surgeons: Ongoing legal matters related to royalty payments could affect relationships with design teams.

Next Steps

• A conference call hosted by the company's management on July 30, 2025, at 4:30 p.m. ET to discuss the second quarter 2025 results.

Key Dates

Recommendation

The filing presents a mixed financial picture. While CONMED achieved sales growth and a notable increase in adjusted diluted EPS, alongside raising its full-year adjusted EPS guidance, the GAAP net earnings per share and operating income declined. The significant drop in Capital Products sales is a concern, offset by strong Single-use Products growth. The company's focus on operational improvements and supply chain strengthening is positive, but the impact of tariffs adds a new headwind. Given these offsetting factors, a 'hold' recommendation is appropriate, suggesting investors monitor the company's ability to translate operational improvements into consistent GAAP profitability and manage tariff impacts, while benefiting from the positive adjusted earnings trajectory.

Keywords

CONMED, CNMD, Medical Technology, Surgical Devices, Orthopedics, General Surgery, Earnings Report, Financial Results, Q2 2025, Adjusted EPS, Revenue Guidance, Healthcare, MedTech, Supply Chain, Tariffs